In Vitro and In Vivo Characterization of Tebipenem, an Orally Active Carbapenem, against Biothreat Pathogens
Abstract
Bacillus anthracis and Yersinia pestis , the causative pathogens for anthrax and plague, respectively, along with Burkholderia mallei and Burkholderia pseudomallei are potential bioterrorism threats. Tebipenem pivoxil hydrobromide (TBP HBr) (formerly SPR994) is an orally available prodrug of tebipenem, a carbapenem with activity versus multidrug-resistant (MDR) Gram-negative pathogens, including quinolone-resistant and extended-spectrum-β-lactamase-producing Enterobacterales .
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 19, 2021
- Source ID
- 10.1128/aac.02385-20
Entities
People
- Akash Jain
- Christopher D. Kane
- Denise Pfefferle
- Gabriel T. Meister
- Henry Heine
- Lisa M. Pysz
- M. Autumn Smiley
- Michael J Pucci
- Michael J. Hackett
- Michael S. Anderson
- Nicholas P. Clayton
- Sanae Lembirik
- Stephanie A. Halasohoris
- Steven D. Zumbrun
Organizations
- Battelle Memorial Institute
- Biomedical Advanced Research and Development Authority
- Defense Threat Reduction Agency
- United States Army Medical Research Institute of Infectious Diseases
- University of Florida